Lyra Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -3.86 | -100% |
| P/S |
|
159.19 | 33.77 | 371.46% |
|
|
| P/BV |
|
2.77 | 4.83 | -42.55% |
|
|
| P/FCF |
|
0 | 61 | -100% |
|
|
| Ev/Ebitda |
|
-3.87 | -22.17 | -82.54% |
|
|
| Ev/S |
|
162.1 | 22.57 | 618.13% |
|
|
| Ev/FCF |
|
-3.92 | 68.76 | -105.71% |
|
|
| E/P |
|
0 | 0.0178 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-4188.06 | 4.97 | -84331.76% | -6006.18 | -30.27% |
| ROE |
|
-70.1 | 9.61 | -829.29% |
|
|
| ROA |
|
-43.96 | 0.3443 | -12868.02% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
-4023.11 | -25.17 | 15883.68% |
|
|
| ROCE |
|
-73.28 | 15.45 | -574.33% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.412 | -3.68 | -88.79% | -0.2622 | +57.11% |
| Nеt Debt/Ebitda |
|
-0.0694 | -3.44 | -97.98% |
|
|
| Debt/Ratio |
|
0.1885 | 0.1986 | -5.07% |
|
|
| Debt/Equity |
|
0 | 1.66 | -100% |
|
|
| Debt/Net Income |
|
-0.4289 | 10.32 | -104.15% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.541 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9598 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4928 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.541 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
4/10
|
29.83 | -57.64 | -151.75% | ||
| Growth impulse Ebitda in 5 years |
|
295.45 | -90.94 | -424.88% | ||
| Growth impulse Net Income in 5 years |
|
289.32 | -97.8 | -395.83% | ||
| Growth impulse FCF in 5 years |
|
359.65 | -108.72 | -430.8% | ||
| Growth impulse EPS in 5 years |
|
-51.03 | -142.05 | -64.08% |
IP Score
4.06/10
